Clinical Outcomes in Patients With Dilated Cardiomyopathy and Ventricular Tachycardia

Katja Zeppenfeld,Adrianus P Wijnmaalen,Micaela Ebert,Samuel H Baldinger,Antonio Berruezo,Valentina Catto,Marmar Vaseghi,Arash Arya,Saurabh Kumar,Marta de Riva,Thomas Deneke,Thomas Gaspar,Kyoko Soejima,Nienke van Rein,Usha B Tedrow, Chistopher Piorkowski,Kalyanam Shivkumar,Corrado Carbucicchio,Gerhard Hindricks,William G Stevenson

Journal of the American College of Cardiology（2022）

引用 11|浏览11

暂无评分

摘要

Patients with DCM needing RFCA for VT are a high-risk group. Following RFCA, approximately one-half remain free of VT recurrence. Early VT recurrence with LVEF ≤32% identifies those at very high risk for mortality or HTx, and screening for mechanical support or HTx should be considered. Late VT recurrence after RFCA does not predict worse outcome.

查看译文

关键词

mortality,nonischemic cardiomyopathy,radiofrequency catheter ablation,VT recurrence

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要